Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer cells in the phase\u00e2 $ 3 SIGN CRC test

.Competing passions.S.K.: Stock as well as Other Ownership Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Role: AbbVie, Amal Therapeutics, AstraZeneca/MedImmune, Bayer Health, Bicara Rehabs, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Effort BioMedicines, Fire Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Medical Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Drugs, Lilly, Lutris, Merck, Mirati Rehabs, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Research Study Backing: Amgen (Inst), Collection BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Previously Pfizer. Supply as well as Other Ownership Passions: Pfizer. J.P.: Employment: Previously Pfizer. Stock and also Various Other Possession Claims: Pfizer. F.C.: Consulting or Advisory Task: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Analysis Funding: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Duty: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Research Study Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Role: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or even Advisory Duty: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapies, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, Shire, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Study Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Analysis Financing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health And Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Work: Pfizer. Supply as well as Other Ownership Interests: Pfizer. X.Z.: Employment: Pfizer. Assets and also Other Ownership Stakes: Pfizer. Patents, Royalties, Various Other Copyright: Johns Hopkins College. P.H.: Employment: Pfizer. Supply and Other Ownership Claims: Pfizer. T.X.: Work: Pfizer. Stock and Other Ownership Stakes: Pfizer. R.Y.: Consulting or Advisory Job: Range BioPharma/Pfizer, Mirati Therapeutics, Zai Laboratory, Amgen. Investigation Backing: Assortment BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Rehab (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Duty: Selection BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapies, MSD, NeoPhore, Novartis, Ona Rehabs, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Rehab, Seagen Inc., Servier, Taiho Pharmaceutical, Tessa Rehab, TheraMyc. Other Connection: Amgen, Range Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Research Study UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de Los Angeles Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Contra el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Wellness KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Rehabs, PeerView Principle for Medical Learning, Pfizer, PharmaMar, Physicansu00e2 $ Learning Information, Sanofi-Aventis, Servier, Taiho Drug.